抗腫瘤抗生素是由微生物產(chǎn)生的具有抗腫瘤活性的化學(xué)物質(zhì)。這種微生物產(chǎn)生的抗生素具有獨特的分子結(jié)構(gòu)、新穎的作用機制和高效的生物活性[1]。目前，抗腫瘤抗生素的研究已取得多方面進(jìn)展，并且多種抗腫瘤抗生素應(yīng)用于臨床，均收到了良好的療效。如放線菌素、鹽酸阿霉素、表柔比星和博來霉素等[2][3]。百靈威作為專業(yè)試劑供應(yīng)商，供應(yīng)抗腫瘤抗生素、抗腫瘤化合物等多種產(chǎn)品。
■ 產(chǎn)品列表
| 產(chǎn)品編號 |
英文名稱 |
中文名稱 |
CAS |
作用靶點 |
| 338112 |
Actinomycin D, 98% |
放線菌素 D, 98% |
50-76-0 |
N/A |
| 113424 |
Doxorubicin hydrochloride, 98% |
鹽酸阿霉素, 98% |
25316-40-9 |
DNA topoisomerase II抑制劑 |
| 194237 |
Epirubicin hydrochloride, 98% |
表柔比星鹽酸鹽, 98% |
56390-09-1 |
DNA topoisomerase II抑制劑 |
| 573584 |
Geldanamycin, 99% |
格爾德霉素, 99% |
30562-34-6 |
HSP90抑制劑 |
| 135072 |
Mithramycin A |
光輝霉素A |
18378-89-7 |
Polymerase抑制劑 |
| 948477 |
Rapamycin, 98% |
雷帕霉素, 98% |
53123-88-9 |
mTOR抑制劑 |
| 282611 |
Wortmannin, 98% |
渥曼青霉素, 98% |
19545-26-7 |
PI3K抑制劑 |
| BIZ0413 |
Zeocin |
博來霉素 |
11031-11-1 |
DNA Synthesis抑制劑 |
更多產(chǎn)品
References
[1] Wang L, Cheng X, Huang C, et al. Rapamycin protects cardiomyocytes against anoxia/reoxygenation injury by inducing autophagy through the PI3k/Akt pathway[J]. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35(1): 10-15.
[2] Baluk P, Yao L C, Flores J, et al. Rapamycin Reverses Lymphatic Abnormalities In A Transgenic Mouse Model Of Pulmonary Lymphangiectasia[M]//B52. NEONATAL LUNG DISEASE: FROM BENCH TO BABIES. American Thoracic Society, 2016: A3866-A3866.
[3] Das D, Rameshbabu A P, Ghosh P, et al. Biocompatible nanogel derived from functionalized dextrin for targeted delivery of doxorubicin hydrochloride to MG 63 cancer cells[J]. Carbohydrate Polymers, 2017, 171: 27-38.
■ 產(chǎn)品列表
| 產(chǎn)品編號 |
英文名稱 |
中文名稱 |
CAS |
作用靶點 |
| 381488 |
Ara-G hydrate, 98% |
阿糖鳥苷, 98% |
38819-10-2 |
DNA/RNA Synthesis抑制劑 |
| 274584 |
Carboplatin, 98% |
碳鉑, 98% |
41575-94-4 |
DNA/RNA Synthesis抑制劑 |
| 258050 |
2-Chloro-2'-deoxyadenosine, 99% |
2-氯-2'-脫氧腺苷, 99% |
4291-63-8 |
DNA/RNA Synthesis抑制劑 |
| 275688 |
cis-Diamineplatinum(II) dichloride, 99% |
順式-二氨二氯化鉑, 99% |
15663-27-1 |
DNA/RNA Synthesis抑制劑 |
| 180939 |
5-Fluorouracil, 99% |
5-氟尿嘧啶, 99% |
51-21-8 |
DNA/RNA Synthesis抑制劑 |
| 271269 |
Gemcitabine hydrochloride, 99% |
鹽酸吉西他濱, 99% |
122111-03-9 |
DNA/RNA Synthesis抑制劑 |
| 251696 |
Oxaliplatin, 95% |
奧沙利鉑, 95% |
61825-94-3 |
DNA/RNA Synthesis抑制劑 |
| 996037 |
Afatinib, 98% |
阿法替尼, 98% |
850140-72-6 |
EGFR抑制劑 |
| 341249 |
Erlotinib, 98% |
埃羅替尼, 98% |
183321-74-6 |
EGFR抑制劑 |
| 831262 |
Lapatinib, 98% |
拉帕替尼, 98% |
231277-92-2 |
EGFR抑制劑 |
| 795123 |
Lapatinib ditosylate, 98% |
二甲苯磺酸拉帕替尼, 98% |
388082-77-7 |
EGFR抑制劑 |
| 625238 |
Entinostat, 99% |
恩替諾特, 99% |
209783-80-2 |
HDAC抑制劑 |
| 837002 |
Panobinostat, 98% |
帕比司他, 98% |
404950-80-7 |
HDAC抑制劑 |
| 303595 |
Trichostatin A, 98% |
曲古柳菌素A, 98% |
58880-19-6 |
HDAC抑制劑 |
| 1349106 |
Ruxolitinib phosphate salt, 99% |
魯索利替尼磷酸鹽, 99% |
1092939-17-7 |
JAK抑制劑 |
| 1430418 |
Tofacitinib citrate, 99% |
檸檬酸托法替尼, 99% |
540737-29-9 |
JAK抑制劑 |
| 912849 |
Tofacitinib, 99% |
托法替尼, 99% |
477600-75-2 |
JAK抑制劑 |
| 951485 |
Ruxolitinib, 99% |
魯索替尼, 99% |
941678-49-5 |
JAK抑制劑 |
| 369172 |
6-Amino-3-methylpurine, 90% |
6-氨基-3-甲基嘌呤, 90% |
5142-23-4 |
PI3K抑制劑 |
| 268623 |
Quercetin, 98% |
槲皮素, 98% |
117-39-5 |
PI3K抑制劑 |
| 812864 |
Axitinib, 98% |
阿西替尼, 98% |
319460-85-0 |
VEGFR2抑制劑 |
| 1239124 |
Ponatinib, 99% |
帕納替尼, 99% |
943319-70-8 |
VEGFR2抑制劑 |
| 814262 |
Vandetanib, 99% |
凡德他尼, 99% |
443913-73-3 |
VEGFR2抑制劑 |
| 1109982 |
Vatalanib dihydrochloride, 99% |
瓦他拉尼堿二鹽酸鹽, 99% |
212141-51-0 |
VEGFR2抑制劑 |
更多產(chǎn)品
■相關(guān)產(chǎn)品